Integra Deferred Long Term Liab from 2010 to 2025
| IART Stock | USD 21.69 0.32 1.45% |
Deferred Long Term Liabilities | First Reported 2010-06-30 | Previous Quarter 61.7 M | Current Value 70.7 M | Quarterly Volatility 52.4 M |
Check Integra LifeSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integra LifeSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 147.9 M, Interest Expense of 74.2 M or Total Revenue of 1.7 B, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 3.0E-4 or PTB Ratio of 1.07. Integra financial statements analysis is a perfect complement when working with Integra LifeSciences Valuation or Volatility modules.
Integra | Deferred Long Term Liab |
Latest Integra LifeSciences' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Integra LifeSciences Holdings over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Integra LifeSciences' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Integra LifeSciences' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Integra Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 55,129,711 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 86.31 | |
| Mean Deviation | 34,987,622 | |
| Median | 58,190,677 | |
| Standard Deviation | 47,584,527 | |
| Sample Variance | 2264.3T | |
| Range | 154.9M | |
| R-Value | 0.24 | |
| Mean Square Error | 2283.1T | |
| R-Squared | 0.06 | |
| Significance | 0.37 | |
| Slope | 2,425,864 | |
| Total Sum of Squares | 33964.3T |
Integra Deferred Long Term Liab History
About Integra LifeSciences Financial Statements
Integra LifeSciences shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Integra LifeSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Integra LifeSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Integra LifeSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 72.8 M | 58.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.